Hemopericardium associated with a tyrosine kinase inhibitor in a patient with leukemia




Eduardo A. Severino-Antonio, Departamento de Medicina Interna, Hospital General de Zona No. 47 Vicente Guerrero, Instituto Mexicano del Seguro Social, Ciudad de México, México
Juan A. Zúñiga-Euroza, Departamento de Medicina Interna, Hospital General de Zona No. 47 Vicente Guerrero, Instituto Mexicano del Seguro Social, Ciudad de México, México


Ponatinib is the only treatment option in chronic myeloid leukemia with T315I mutation, being the most cardiotoxic agent of the tyrosine kinase inhibitors, with multiple adverse events such as pericarditis, arrhythmias, among others. Adverse events were reported in up to 64%, being this the first publication where it is associated with hemopericardium, due to alterations in cardiac homeostasis by suppressing about 60 kinases, which was detected by imaging study and resolved by surgical drainage. Therefore, it is proposed to be included as a manifestation of cardiotoxicity, emphasizing the lack of a systematic model to predict the cardiotoxicity index in this group of patients.



Keywords: Cardiotoxicity. Hemopericardium. Chronic myeloid leukemia. Tyrosine kinase inhibitor.